I had the honor of interviewing Kyle Cetrulo, CEO of AuxoCell Laboratories. In this interview, we explore the upcoming Future of Regenerative Medicine Congress, as well as future directions for regenerative medicine at large. Enjoy. [Read more…]
Google has been massively (and quietly) increasing its presence in the regenerative medicine sector for several years.
In February 2016, Google’s life sciences business, Verily Life Sciences, announced it was negotiating terms to lease a giant 400,000-square-foot facility formerly occupied by Onyx Pharmaceuticals, a company acquired by Amgen for $9.7 billon in 2013.
The facility in Mountain View, California, is about 30 miles north of Alphabet Inc., the holding company for Google (NASDAQ: GOOG). It could support as many as 1,000 Verily Life Sciences employees. Land is also included in lease, a rarity in the Bay Area, allowing Verily the potential for future expansion. [Read more…]
BioInformant is proud to announce its sponsorship of the Future of Regenerative Medicine Congress, May 19-21, 2017 in Teaneck, NJ.
What is the Future of Regenerative Medicine Congress?
“The Future of Regenerative Medicine Congress: Extending and Improving Life with Perinatal, Adipose, and Bone Marrow Cellular Therapy” is a three-day educational conference designed for researchers and medical practitioners that work directly in the field of regenerative medicine. [Read more…]
Boston BioLife (www.bostonbiolife.com) is a cutting-edge organization that provides workshops for physicians and scientists interested in learning regenerative medicine. Its mission is to facilitate the introduction of emerging life sciences technologies to scientists and healthcare providers. [Read more…]
Mesoblast has been granted a key patent by the United States Patent and Trademark Office (USPTO) for use of its Mesenchymal Precursor Cells (MPCs) in the treatment of rheumatic diseases, including rheumatoid arthritis (RA). Mesoblast is global company that specializes in developing cell-based therapies that utilize mesenchymal precursor cells (MPCs) and mesenchymal stem cells (MSCs).
The Company’s patent portfolio in the United States for the treatment of RA and related conditions “comprises the newly and recently granted patents, US 9,381,216 and US 9,265,796, which cover treatment of rheumatic diseases by administration of STRO-1 positive MPCs.”
According to Dr. Allan Gibofsky, Professor at Weill Cornell Medical College, “The trial used standardized parameters consistent with United States Food and Drug Administration (FDA) guidance for RA product development. Importantly, there was consistency observed in the dose-related responses for clinical symptoms, physical function and disease activity parameters at 12 weeks in line with the trial’s pre-specified efficacy endpoints.”